Bayer could benefit from home advantage in St. Louis Roundup cancer trial: experts

Bayer could benefit from home advantage in St. Louis Roundup cancer trial: experts
ST. LOUIS (Reuters) – Bayer AG (BAYGn.DE), facing an upcoming trial in St. Louis over allegations that its Roundup weed killer causes cancer, has recruited Missouri-based expert witnesses to make its case in a place where it has century-old roots but where juries often hit companies with huge damages. FILE PHOTO: The logo of Bayer AG is pictured at the... Read More

Bayer welcomes judge’s call for damages to be cut in $2 billion glyphosate case

Bayer welcomes judge’s call for damages to be cut in $2 billion glyphosate case
FILE PHOTO: The logo of Bayer AG is pictured at the facade of the historic headquarters of the German pharmaceutical and chemical maker in Leverkusen, Germany, May 14, 2019. REUTERS/Wolfgang Rattay/File Photo FRANKFURT (Reuters) – Germany’s Bayer AG on Friday welcomed a conditional ruling by a U.S. judge calling for the reduction of a $2 billion damages award to a... Read More

Bayer welcomes judge’s call for new trial in $2 billion glyphosate case

Bayer welcomes judge’s call for new trial in $2 billion glyphosate case
FILE PHOTO: The logo of Bayer AG is pictured at the facade of the historic headquarters of the German pharmaceutical and chemical maker in Leverkusen, Germany, May 14, 2019. REUTERS/Wolfgang Rattay/File Photo FRANKFURT (Reuters) – Germany’s Bayer AG (BAYGn.DE) on Friday welcomed a conditional ruling by a U.S. judge calling for a retrial of the case of a couple awarded... Read More

UnitedHealth boosts earnings forecast, set to pass price discounts to patients

UnitedHealth boosts earnings forecast, set to pass price discounts to patients
(Reuters) – UnitedHealth Group Inc (UNH.N) will stick with its decision to pass on drug maker discounts to patients to help them beat rising medicine prices despite the U.S. government having withdrawn a similar proposed policy in its health programs, its top executive said on Thursday. “You can expect us not to change our stance on rebates,” Chief Executive Officer... Read More

Takeda kicks off sale of Western European drugs: sources

Takeda kicks off sale of Western European drugs: sources
FRANKFURT/LONDON (Reuters) – Japan’s Takeda Pharmaceutical Co (4502.T) has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters. Takeda Pharmaceutical Co’s logo is seen at its new headquarters in Tokyo, Japan, July 2,... Read More

As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff

As steep patent cliff looms, Shionogi moves to develop its own U.S. sales staff
TOKYO (Reuters) – For much of its 141-year history, Japan’s Shionogi & Co Ltd (4507.T) has played safe when selling its drugs in the United States and other overseas markets – relying on bigger partners to promote its products and avoiding the cost of maintaining a large sales force. Isao Teshirogi, President and CEO at Shionogi & Co Ltd, speaks... Read More

Stock futures flat after JPMorgan results; Goldman Sachs, Wells Fargo eyed

Stock futures flat after JPMorgan results; Goldman Sachs, Wells Fargo eyed
(Reuters) – U.S. stock futures were trading flat on Tuesday as investors parsed through the earnings report from JPMorgan Chase and awaited results from Wall Street banks such as Goldman Sachs and Wells Fargo. Traders work on the floor of the New York Stock Exchange shortly after the opening bell in New York, U.S., July 12, 2019. REUTERS/Lucas Jackson The... Read More

Johnson & Johnson beats profit estimates on pharma strength, raises sales outlook

Johnson & Johnson beats profit estimates on pharma strength, raises sales outlook
The Johnson & Johnson logo is displayed on a screen on the floor of the New York Stock Exchange (NYSE) in New York, U.S., May 29, 2019. REUTERS/Brendan McDermid (Reuters) – Johnson & Johnson (JNJ.N) hiked its full-year operational sales forecast as strong demand for its cancer drugs Darzalex and Imbruvica helped it beat estimates for second-quarter profit on Tuesday.... Read More